Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI
BACKGROUND: Patients who undergo percutaneous coronary intervention (PCI) are at increased risk for recurrent cardiovascular events despite aggressive medical therapy. METHODS AND RESULTS: This post hoc analysis focused on the subset of patients with prior PCI enrolled in REDUCE-IT (Reduction of Car...
Main Authors: | Ballantyne, C.M (Author), Bhatt, D.L (Author), Brinton, E.A (Author), Budoff, M.J (Author), Doyle, R.T., Jr (Author), Gibson, C.M (Author), Giugliano, R.P (Author), Granowitz, C. (Author), Jacobson, T.A (Author), Jiao, L. (Author), Juliano, R.A (Author), Ketchum, S.B (Author), Miller, M. (Author), Peterson, B.E (Author), Pinto, D. (Author), Steg, P.G (Author), Tardif, J.-C (Author), Verma, S. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
American Heart Association Inc.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
by: Ballantyne, C.M, et al.
Published: (2022) -
Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
by: Christie M. Ballantyne, et al.
Published: (2019-02-01) -
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
by: Wenjun Fan, et al.
Published: (2020-04-01) -
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
by: Peter P. Toth, et al.
Published: (2020-09-01) -
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
by: Jia X, et al.
Published: (2020-01-01)